Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster logo

Implementation Science Group (Cochrane GI)

As defined by the National Cancer Institute at the National Institutes of Health, implementation science is the study of methods to promote the adoption and integration of evidence-based practices, interventions, and policies into routine health care and public health settings to improve the impact on population health.

The Implementation Science Group at the Farncombe Family Digestive Health Research Institute is leading Cochrane Gut, which synthesizes evidence from randomized controlled trials and observational studies in humans, as well as animal studies, to answer patient-important questions on the diagnosis, prevention, treatment and rehabilitation of gastrointestinal diseases, including functional disorders of the gut, and inflammatory bowel disease, both in adults and children. The members of the Implementation Science Group also provide content expertise and methodological support for clinical practice guidelines on gastrointestinal diseases conducted by Canadian, US and international professional gastroenterology associations. They lead research that advances the methods for knowledge synthesis and clinical practice guidelines and provide formal training to local, national and international researchers who wish to be involved in knowledge synthesis and clinical practice guidelines.

Investigators:

Cochrane Gut: https://gut.cochrane.org/

Selected References:

Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, Telford JJ, Leontiadis GI. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Am J Gastroenterol 2022;117(4):542-558.

Kanno T, Yuan Y, Tse F, Howden CW, Moayyedi P, Leontiadis GI. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2022;1(1):CD005415.

Tse F, Liu J, Yuan Y, Moayyedi P, Leontiadis GI. Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Cochrane Database Syst Rev 2022;3(3):CD009662.

Karam SG, Darzi AJ, Bognanni A, Morsi RZ, Tannous EE, Charide R, Choe SI, Stalteri R, Lee Y, Piggott T, Jewell L, Schünemann F, Langendam M, Parmelli E, Saz-Parkinson Z, Roi A, Vilahur N, Vali Y, Waffenschmidt S, Owens DK, Leontiadis GI, Moayyedi P, Brozek JL, Schünemann HJ. Analytical frameworks in colorectal cancer guidelines: development of methods for systematic reviews, their application and practical guidance for their use. J Clin Epidemiol 2022;149:206-216.

Benchimol EI, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Jones JL. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines. Gastroenterology 2021;161(2):669-680.

Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Benchimol EI. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. Gastroenterology 2021;161(2):681-700.

Tse F, Moayyedi P, Waschke KA, MacMillan M, Forbes N, Carroll MW, Carman N, Leontiadis GI. COVID-19 Vaccination in Patients With Inflammatory Bowel Disease: Communiqué From the Canadian Association of Gastroenterology. J Can Assoc Gastroenterol 2021;4(1):49.

Moayyedi P, MacQueen G, Bernstein CN, Vanner S, Bercik P, Madsen KL, Surette M, Rioux JD, Dieleman LA, Verdú E, de Souza RJ, Otley A, Targownik L, Lavis J, Cunningham J, Marshall DA, Zelinsky S, Fernandes A. IMAGINE Network’s Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. BMJ Open. 2020 Oct 21;10(10):e041733.

Pittayanon R, Lau JT, Leontiadis GI, Tse F, Yuan Y, Surette M, Moayyedi P. Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review. Gastroenterology 2020;158(4):930-946.

Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology 2019;157(1):97-108.

Moayyedi P, Benchimol EI, Armstrong D, Yuan C, Fernandes A, Leontiadis GI. Joint Canadian Association of Gastroenterology and Crohn’s Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease. J Can Assoc Gastroenterol 2020;3